The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .
Plasma Carotenoids and Tocopherols and Risk of Myocardial Infarction in a Low-Risk Population of US Male Physicians
Background —Increased intake of carotenoids and vitamin E may protect against myocardial infa rct ion ( MI ) . However , prospect i ve data on blood levels of carotenoids other than & bgr;-carotene and vitamin E ( tocopherol ) and risk of MI are sparse . Methods and Results —We conducted a prospect i ve , nested case-control analysis among male physicians without prior history of cardiovascular disease who were followed for up to 13 years in the Physicians ’ Health Study . Sample s from 531 physicians diagnosed with MI were analyzed together with sample s from paired control subjects , matched for age and smoking , for 5 major carotenoids ( & agr;- and & bgr;-carotene , & bgr;-cryptoxanthin , lutein , and lycopene ) , retinol , and & agr;- and & ggr;-tocopherol . Overall , we found no evidence for a protective effect against MI for higher baseline plasma levels of retinol or any of the carotenoids measured . Among current and former smokers but not among never-smokers , higher baseline plasma levels of & bgr;-carotene tended to be associated with lower risk ( P for interaction=0.02 ) . Men with higher plasma levels of & ggr;-tocopherol tended to have an increased risk of MI ( P for trend=0.01 ) . Conclusions —These prospect i ve data do not support an overall protective relation between plasma carotenoids or tocopherols and future MI risk among men without a history of prior cardiovascular disease
The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .